I. INTRODUCTION {#acm20197-sec-0001}
===============

Stereotactic radiosurgery (SRS) is the process of delivering a high dose of external beam radiation to a small intracranial target in a single fraction using $\,^{60}\text{Co}$ sources, medical linear accelerators, or charged particle beams guided by an external frame system. Collimated radiation beams are precisely positioned and focused onto a target within the brain to deliver a high dose of localized radiation. An advantage of SRS is the prevention of damage to surrounding healthy tissue because of the steep dose gradient around the target volume. As suggested by normal tissue complication probability modeling for radiosurgery,^(^ [^1^](#acm20197-bib-0001){ref-type="ref"} ^)^ a high degree of conformity of the prescription dose to target volume should be achieved to allow safe treatment of the target. Conformity Index (CI) is the ratio of the prescription volume to the target volume, as defined in the Radiation Therapy Oncology Group (RTOG) radiosurgery guidelines in 1993.^(^ [^2^](#acm20197-bib-0002){ref-type="ref"} ^--^ [^4^](#acm20197-bib-0004){ref-type="ref"} ^)^ CI is useful for evaluating competing plans for the same patient or comparing different modalities. Dose volume histograms (DVH) summarize the dose distribution information for a region of interest or anatomical structure and identify characteristics such as dose uniformity and hot or cold spots. DVHs may be a preliminary step in evaluating statistics such as tumor control and normal tissue complication probabilities.^(^ [^5^](#acm20197-bib-0005){ref-type="ref"} ^,^ [^6^](#acm20197-bib-0006){ref-type="ref"} ^)^ However, when comparing a large number of plans, DVHs contain large amounts of data and make the comparison difficult and cumbersome.

Radiosurgery has evolved over the past decade with the development of new treatment delivery technologies such as dedicated radiosurgery linear accelerators. In the past, it has been reported that linear accelerator‐based SRS is less conformal than gamma knife SRS.^(^ [^4^](#acm20197-bib-0004){ref-type="ref"} ^,^ [^7^](#acm20197-bib-0007){ref-type="ref"} ^,^ [^8^](#acm20197-bib-0008){ref-type="ref"} ^)^ However, linear accelerator‐based SRS has become highly sophisticated, evolving from circular arc and multiple isocenters per target to dynamic conformal arcs (DCA) based on a single isocenter. The dynamic conformal arc is a method of linear accelerator‐based SRS that uses multiple arcs rotating about a single isocenter.^(^ [^9^](#acm20197-bib-0009){ref-type="ref"} ^,^ [^10^](#acm20197-bib-0010){ref-type="ref"} ^)^ This method uses the MLC to conform to the target volume every 10 degrees of arc. Recently, it has been reported that improvement in linear accelerator‐based SRS techniques have allowed comparable conformity to that of a gamma knife.^(^ [^11^](#acm20197-bib-0011){ref-type="ref"} ^)^

The impacts of linear accelerator MLC leaf width on stereotactic radiosurgery and radiotherapy plans have been investigated and previously reported.^(^ [^12^](#acm20197-bib-0012){ref-type="ref"} ^--^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ Kubo et al.^(^ [^12^](#acm20197-bib-0012){ref-type="ref"} ^)^ compared the conformity of 3D conformal plans using 1.7 mm, 3 mm and 10 mm leaf width MLCs and found that the smaller leafs produced more normal tissue sparing. IMRT plans for cranial cases were compared using 5 mm and 10 mm MLC leaf widths, and noticeably better sparing of optic structure was observed using 5 mm MLC.^(^ [^13^](#acm20197-bib-0013){ref-type="ref"} ^)^ Monk et al.^(^ [^14^](#acm20197-bib-0014){ref-type="ref"} ^)^ compared the Varian Millennium 120‐MLC (minimal 5 mm leaf) with the BrainLAB (BrainLAB, Munich, Germany) micro‐MLC (minimal 3 mm leaf width) with plans using fixed non‐coplanar beams. They reported a small but statistically significant improvement in dose conformity and organ at risk (OAR) sparing with the 3 mm MLC compared with the 5 mm MLCs. Jin et al.^(^ [^17^](#acm20197-bib-0017){ref-type="ref"} ^)^ used dynamic conformal arcs and IMRS/IMRT techniques to compare the 3 mm micro‐MLC and the 5 mm and 10 mm MLC, and found significant dosimetric differences in the conformity indices between the three MLCs -- with the 3 mm leaf width scoring better. This study also reported that the difference in the conformity index decreases with the target volume and that, as the MLC margin increases in increments of 1 mm, the difference in the conformity indices decreases. Chern et al.^(^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ also compared the 3 mm BrainLAB micro‐MLC (minimal leaf width is 3 mm) and Varian Millennium 120‐MLC (minimal leaf width is 5 mm) using the DCA technique. This paper reported improved dosimetric results using 3 mm as compared to 5‐MLC and for small target volume ($< 1\,\text{cm}^{3}$), they reported as high as 10% improvement, on average, in CI.

Our current study compares the dose distributions between a high‐definition 2.5 mm MLC leaf width ($\text{MLC}_{2.5}$) (High Definition (HD) MLC, Varian Medical Systems, Palo Alto, CA) and a standard 5 mm MLC leaf width ($\text{MLC}_{5}$) (Millennium MLC, Varian Medical Systems, Palo Alto, CA) in the treatment of intracranial lesion using DCA treatment techniques. Clinical patient cases were planned with both MLCs using the same DCA beam paths. Figures of merit (FOM) for plan comparison such as CI, target volume dose coverage, and normal tissue sparing were used to evaluate the superiority of the resulting treatment plans. The effect of target volume on the performance of the two MLCs also was analyzed using simulated and actual patient case data.

II. MATERIALS AND METHODS {#acm20197-sec-0002}
=========================

A. Treatment delivery MLCs {#acm20197-sec-0003}
--------------------------

A Novalis Tx (Varian Medical Systems, Palo Alto, CA) radiosurgical linear accelerator with a high definition (HD) MLC is one machine used by this study. This linear accelerator has 6 MV photon beam energy with a 1000 MU/min maximum dose rate. The Novalis Tx has a maximum possible MLC field size of $22 \times 40\,\text{cm}^{2}$ at isocenter. The 22 cm is formed by 32 leaf pairs of 2.5 mm leaf width in the central part and 28 leaf pairs of 5 mm leaf width in the outer part of the MLC. This HD MLC is referred to as the $\text{MLC}_{2.5}$ in this paper. A Trilogy (Varian Medical Systems, Palo Alto, CA) linear accelerator using a standard 120‐leaf MLC is used as the comparison system in this study. The Trilogy has a 6 MV and 18 MV photon beam energy with a maximum dose rate of 1000 MU/min. The 120‐leaf MLC has two leaf widths with the inner 40 leaf pairs having a 5 mm leaf width and the outer 20 leaf pairs having 10 mm leaf width. The maximum field size for the standard120‐leaf MLC is $40 \times 40\,\text{cm}^{2}$. This standard Trilogy MLC is referred to as the $\text{MLC}_{5}$ in this paper. All target volumes in this study were small and utilized the inner set of leaves to enable a direct comparison of 2.5 mm and 5 mm leaf widths.

B. Simulated target volume {#acm20197-sec-0004}
--------------------------

A simulated patient case was created to study solely the effect of target volume size and shape on the performance of the two MLC systems. For an example patient case, a sphere was created as the target volume with volumes ranging from 0.11 to $39\,\text{cm}^{3}$. The simulated sphere was centrally located within the patient head.

C. Study patients {#acm20197-sec-0005}
-----------------

A total of 43 stereotactic radiosurgery patients were selected for this study. These patients were selected from 278 patients treated since January 2007 in our institution. All of these (except one patient treated with IMRS) were treated with DCA method for SRS. Patient selection was based on including a wide variety of shapes and volumes of radiosurgery targets. The selected cases included 11 patients with acoustic neuromas, 3 with meningiomas, 4 with arteriovenous malformations, 19 with metastatic lesions, 3 with glomus tumors, 1 with an astrocytoma, 1 with a pineocytoma and 1 with a pituitary adenoma. The patients\' ages ranged from 26 to 81 yrs old, with an average age of 55 yrs. The volume of targets ranged from 0.07 to $40.57\,\text{cm}^{3}$ and the average volume was $5.9\,\text{cm}^{3}$. All these patients were planned using DCA technique for both $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$.

D. Treatment plan creation {#acm20197-sec-0006}
--------------------------

The DCA technique was used for all the plans in this study. In this technique, the MLC automatically conforms to the target volume outline via software methods. [Figure 1](#acm20197-fig-0001){ref-type="fig"} shows the difference via beam\'s eye view (BEV) between the $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ conforming to a target volume. The treatment plans were created using a dedicated radiosurgical planning system (iPlan RT Dose 3.0, BrainLAB, Germany). A planning CT image study was obtained for each patient. Patient images were acquired with a stereotactic localization frame (BrainLAB, Germany) attached to the patient\'s head. The CT imaging slice thickness was 0.625 mm. Magnetic resonance (MR) images were carried out for each patient at a similar slice thickness. The CT and MR were registered together to allow for MR‐based target delineation. Target volumes and critical structures were outlined by our radiation oncologist and neurosurgeon during planning process. A DCA plan was created using 4 or 5 non‐coplanar dynamic conformal arcs averaging 100° per arc. The treatment planning system using the MLC automatically creates a field shape that conforms to the target outlines as shown in [Fig. 1](#acm20197-fig-0001){ref-type="fig"}. The collimator angles were set to 90° and, in few cases, it was changed to improve MLC conformity with the target volume. For non‐metastatic lesions, no margin was added to create a planning target volume (PTV). For all metastatic lesions, a margin of 1 mm was added to create a PTV. To compare the $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ plans, all treatment parameters were identical for planning purposes.

![Graphical display of BEV for 100° arc for $\text{MLC}_{2.5}$ (a) and $\text{MLC}_{5}$ (b). These two views show MLC\'s leaf position for every ten degrees surrounding the target volume (in blue). The leaf width between the two views for the 2.5 mm and 5 mm leaf width is shown; the yellow outline demonstrates the difference in conformality of the two MLC systems.](ACM2-11-197-g001){#acm20197-fig-0001}

E. Treatment plan evaluation {#acm20197-sec-0007}
----------------------------

The evaluation of competing MLC‐based plans was performed using isodose displays with medical images, DVHs, and figures of merits (FOM). The use of isodose displays and DVHs are standard plan evaluation tools used in the clinical environment. Dose volume histograms (DVHs) were generated for each lesion and for the surrounding normal brain tissue. In this analysis, the use of FOM allows for a rapid and objective assessment on the quality of the two treatment plans. This section describes the FOMs used for evaluating the plan differences in this study.

### E.1 Target coverage {#acm20197-sec-0008}

Target coverage (TC) is defined as the percent volume of the tumor volume receiving the prescription dose. Typically, the coverage index should be at least 95%. In this study, the prescription isodose surface was selected as the greatest isodose surface covering $\geq 95\%$ of the target volume and delivering 95% of the prescription dose to 99% of target volume.^(^ [^11^](#acm20197-bib-0011){ref-type="ref"} ^,^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ After the prescription isodose surface was determined for the $\text{MLC}_{2.5}$, the equivalent isodose surface was used for the $\text{MLC}_{5}$. [Table 1](#acm20197-tbl-0001){ref-type="table-wrap"} shows data for an example patient case with a target volume of $4.93\,\text{cm}^{3}$. Using this example data in [Table 1](#acm20197-tbl-0001){ref-type="table-wrap"}, the 88% isodose surface covers 95.5% of the target volume, which satisfies the first condition. The second condition is also satisfied since 95% of this prescription isodose value $(88\% \times 95\% = 83.6\%)$ covers 99% of the target volume. In this analysis, if the first condition was fulfilled and the second condition was not fulfilled, then a lower isodose surface was selected until both conditions are satisfied.

###### 

An example patient case demonstrating prescription isodose selection method for study (target volume for this case = $4.93\,\text{cm}^{3}$).

  *PI* [a](#acm20197-tbl-note-0001){ref-type="fn"}   *Target Coverage (%)*   *95% of PI*   *CI*    *PITV Ratio*
  -------------------------------------------------- ----------------------- ------------- ------- --------------
  79                                                 100.00                  75.05         2.293   2.293
  80                                                 100.00                  76.00         2.209   2.209
  81                                                 99.94                   76.95         2.162   2.161
  82                                                 99.89                   77.90         2.083   2.081
  83                                                 99.72                   78.85         2.013   2.007
  84                                                 99.50                   79.80         1.951   1.941
  85                                                 98.94                   80.75         1.871   1.852
  86                                                 98.05                   81.70         1.798   1.763
  87                                                 97.00                   82.65         1.720   1.669
  88                                                 95.55                   83.60         1.656   1.582
  89                                                 93.49                   84.55         1.615   1.510
  90                                                 90.60                   85.50         1.590   1.441
  91                                                 87.09                   86.45         1.500   1.306
  92                                                 84.09                   87.40         1.427   1.200
  93                                                 79.13                   88.35         1.368   1.083
  94                                                 73.79                   89.30         1.276   0.941
  95                                                 66.78                   90.25         1.209   0.807
  96                                                 57.93                   91.20         1.165   0.675
  97                                                 47.30                   92.15         1.118   0.529
  98                                                 34.61                   93.10         1.092   0.378
  99                                                 19.76                   94.05         1.061   0.210

Prescription isodose value

### E.2 Normal tissue sparing {#acm20197-sec-0009}

To evaluate the normal tissue sparing associated with the MLC systems, an anatomical structure consisting of an adjacent tissue shell was created to surround the target volume by adding a 1 cm margin. This is similar to the method described by Chern et al.^(^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ The DVH for this normal tissue structure was computed to assess the dose volume values for selected points on the DVH curve. The normal tissue volume 50 ($\text{NTV}_{50}$) was calculated which is the normal tissue receiving 50% of the prescription isodose (PI). The $\text{NTV}_{70}$ and $\text{NTV}_{90}$ receiving 70% and 90% of prescription isodose, respectively, were also computed from the DVH.

To assess normal tissue sparing, a normal tissue difference (NTD) was calculated. NTD is the difference between the volume of normal tissue receiving a certain dose utilizing $\text{MLC}_{5}$ and the volume receiving the same dose using $\text{MLC}_{2.5}$. This is illustrated in [Fig. 2](#acm20197-fig-0002){ref-type="fig"} with a schematic diagram showing the striped region as the area calculated for the NTD. For example, the NTD for tissue receiving 50% of the prescription isodose ($\text{NTD}_{50}$) is calculated as follows: $$NTD_{50} = NTV_{50}^{MLC_{5mm}} - NTV_{50}^{MLC_{2.5mm}}$$

where $NTV_{50}^{MLC_{5mm}}$ and $NTV_{50}^{MLC_{2.5mm}}$ are the volume of normal tissue receiving 50% of PI with the use of $\text{MLC}_{5}$ and $\text{MLC}_{2.5}$, respectively.

![Schematic illustrating the definition of normal tissue difference NTD.](ACM2-11-197-g002){#acm20197-fig-0002}

### E.3 Target conformity {#acm20197-sec-0010}

Conformity indices are used to compare competing plans, evaluate treatment technique, and assess clinical complications by quantifying the dose conformity to a target volume. Several different indices have been reported to evaluate the conformity of prescription isodose surface to the target volume. In 1993, Radiation Therapy Oncology Group (RTOG) proposed routine evaluation of stereotactic radiotherapy treatment plans based on reference isodose value and reference isodose volume and target volume.^(^ [^2^](#acm20197-bib-0002){ref-type="ref"} ^--^ [^4^](#acm20197-bib-0004){ref-type="ref"} ^,^ [^7^](#acm20197-bib-0007){ref-type="ref"} ^,^ [^19^](#acm20197-bib-0019){ref-type="ref"} ^)^ The RTOG proposed the conformity index as PITV^(^ [^4^](#acm20197-bib-0004){ref-type="ref"} ^,^ [^7^](#acm20197-bib-0007){ref-type="ref"} ^,^ [^8^](#acm20197-bib-0008){ref-type="ref"} ^,^ [^11^](#acm20197-bib-0011){ref-type="ref"} ^,^ [^19^](#acm20197-bib-0019){ref-type="ref"} ^,^ [^20^](#acm20197-bib-0020){ref-type="ref"} ^)^ which is defined as: $$PITV = \frac{PIV}{TV}$$

where TV is the target volume and PIV is the prescription isodose volume.

The RTOG Conformity index, or *PITV* ratio, is the most frequently used conformity index to compare the conformity of treatment plans from different radiosurgery delivery systems.^(^ [^4^](#acm20197-bib-0004){ref-type="ref"} ^,^ [^7^](#acm20197-bib-0007){ref-type="ref"} ^,^ [^8^](#acm20197-bib-0008){ref-type="ref"} ^,^ [^21^](#acm20197-bib-0021){ref-type="ref"} ^--^ [^24^](#acm20197-bib-0024){ref-type="ref"} ^)^ According to the *PITV* ratio, a PITV value equal to 1 corresponds to ideal conformation. A PITV greater than 1 indicates that the irradiated volume is greater than the target volume, which means it includes healthy tissues. If the PITV is less than 1, it indicates that the target volume is partially covered. According to RTOG guidelines, a PITV^(^ [^19^](#acm20197-bib-0019){ref-type="ref"} ^)^ between 1 and 2 is considered a treatment plan of acceptable dose conformity. The treatment plan receives a minor violation judged by RTOG guidelines for a PITV between 2 and 2.5 or 0.9 and 1. The treatment plan is rated a major violation by RTOG standards if the PITV is less than 0.9 or more than 2.5.

The drawback of the *PITV* ratio is that it does not take into account the spatial location and the shape of the prescription isodose volume relative to the TV. If the volume of tissue receiving the prescribed dose is equal to the TV, the *PITV* ratio will be 1 and the treatment plan will receive the same perfect score of 1 regardless whether the prescribed isodose perfectly enclosed the TV or completely missed the TV (i.e. 0% of the TV received the prescribed dose). Therefore, *PITV* ratio can be improved by accounting for coverage of the target volume.

Paddick^(^ [^20^](#acm20197-bib-0020){ref-type="ref"} ^)^ accounted for target volume coverage by proposing a new conformity index as follows: $$CI_{Paddick} = \frac{TV_{PIV}}{TV} \times \frac{TV_{PIV}}{PIV}$$

where $\mathit{TV}_{\mathit{PIV}}$ is the target volume within the prescribed isodose volume *PIV*. This becomes the inverse of the PTIV when the prescription isodose fully covers the target volume.

Paddick\'s Conformity CI was modified by Nakamura et al.^(^ [^7^](#acm20197-bib-0007){ref-type="ref"} ^)^ and expressed as follows: $$CI = \frac{PIV/PVTV}{PVTV/TV}$$

where is the target volume, *PIV* is the prescription isodose volume, *PVTV* is the *TV* included in the prescription isodose surface. The *PIV* equals to the *PVTV* plus the normal tissue NT encompassed by the prescription isodose surface. The numerator of the above equation measures the excess volume of normal tissue within the prescription isodose surface and the denominator measures the target coverage. In this study, we used a similar conformity index method, which is as follows: $$CI = \frac{PIV}{PVTV} = \frac{(PVTV + NT_{V})}{PVTV}$$

where *PIV* is the total volume encompassed by the prescription isodose surface, *PVTV* is the volume of target TV encompassed by the prescription isodose surface, $\mathit{NT}_{V}$ is the volume of the normal tissue encompassed by the prescription isodose surface. It has been demonstrated that prescription isodose surface associated with the minimal CI does not necessarily produce provide adequate coverage. This is due to the fact that, as the coverage of the TV increases, a large amount of NT is included in the PIV and the plan will have higher CI. Therefore, the prescription isodose surface should be chosen that balances conformity and target coverage.

In another report, Paddick et al.^(^ [^25^](#acm20197-bib-0025){ref-type="ref"} ^)^ also proposed a dose gradient index (GI), which is the ratio of the volume of 50% of the prescription isodose to the volume of the prescription isodose to compare plans of equal conformity indices. The GI shows which plan gives the steepest dose falloff outside the target. Other investigators introduced a conformity distance index (CDI).^(^ [^26^](#acm20197-bib-0026){ref-type="ref"} ^)^ The CDI is defined as the average distance between the prescription isodose and the target contour. This parameter accounts for the influence of target size and shape complexity on the conformity of the plan. The CDI is expressed as follows: $$CDI = \frac{(PIV - TV_{PIV}) + (TV - TV_{PIV})}{\frac{1}{2} \times (S_{PIV} + S_{TV})}$$

where $S_{\mathit{PIV}}$ and $S_{\mathit{TV}}$ are the surfaces of $\mathit{TV}_{\mathit{PIV}}$ and *PIV*, respectively. The CDI values were accurately calculated using custom‐developed software by the authors.

III. RESULTS {#acm20197-sec-0011}
============

A. Simulated target study {#acm20197-sec-0012}
-------------------------

In our study, simulated spherical target volumes (ranging from 0.11 to $39\,\text{cm}^{3}$) were analyzed. These targets were created to reduce target shape effects on the CI and evaluate its dependence on the target volume only, for both MLCs. The plotted results show that, while CIs for both MLCs decrease with the target volume, the CI for $\text{MLC}_{2.5}$ for each TV volume is clearly lower than the corresponding CI of $\text{MLC}_{5}$ across the entire range of volumes ([Fig. 3](#acm20197-fig-0003){ref-type="fig"}). [Figure 4](#acm20197-fig-0004){ref-type="fig"} demonstrates that $\text{NTV}_{70}$ and $\text{NTV}_{90}$ also increase with the volume of a spherical target using both MLC and that the $\text{MLC}_{2.5}$ provides better normal tissue sparing.

![Dependence of Conformity Index on target volume for a simulated spherical target using $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$.](ACM2-11-197-g003){#acm20197-fig-0003}

![Comparison of normal tissue sparing capabilities of $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ for a simulated spherical target.](ACM2-11-197-g004){#acm20197-fig-0004}

B. Study patients {#acm20197-sec-0013}
-----------------

[Table 2](#acm20197-tbl-0002){ref-type="table-wrap"} presents the $\text{MLC}_{2.5}$ conformity indices which range from 1.15 to 2.44 with a median of 1.59. The CI range for $\text{MLC}_{5}$ was 1.60 to 2.85 with a median of 1.71. Similar to our results with the simulated target study, these results indicate that the $\text{MLC}_{2.5}$ provides better treatment conformity than $\text{MLC}_{5}$ as judged by the CI values in a range of actual patient tumors. The graph of percentage difference of the conformity indices between $\text{MLC}_{5}$ and $\text{MLC}_{2.5}$ versus target volume is shown ([Fig. 5](#acm20197-fig-0005){ref-type="fig"}). While differences in CIs between the two MLCs decrease with target volume, even at large volumes the $\text{MLC}_{2.5}$ provides better conformity.

###### 

Tumor type, volume and comparison of conformity index between $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ for each patient.

  *Case \#*   *Tumor Type*                                     *Age*   *Gender*   *TV (cm^3^)*   *CI‐* $\mathit{MLC}_{2.5}$   *CI‐* $\mathit{MLC}_{5}$   *% Diff. CI*
  ----------- ------------------------------------------------ ------- ---------- -------------- ---------------------------- -------------------------- --------------
  1           Acoustic Neuroma                                 46      Female     0.070          1.888                        1.936                      2.560
  2           Acoustic Neuroma                                 68      Male       0.187          1.902                        2.083                      9.474
  3           Acoustic Neuroma                                 40      Female     0.327          2.367                        2.720                      14.920
  4           Acoustic Neuroma                                 53      Female     0.351          2.081                        2.470                      18.670
  5           Acoustic Neuroma                                 79      Female     0.382          1.950                        2.150                      10.230
  6           Acoustic Neuroma                                 68      Female     0.411          2.441                        2.849                      16.736
  7           Acoustic Neuroma                                 59      Male       0.505          1.993                        2.331                      16.958
  8           Acoustic Neuroma                                 49      Male       0.823          1.992                        2.198                      10.314
  9           Acoustic Neuroma                                 37      Male       0.836          1.421                        1.622                      14.147
  10          Acoustic Neuroma                                 59      Male       0.867          1.563                        1.637                      4.722
  11          Acoustic Neuroma                                 81      Female     1.103          1.619                        1.735                      7.188
  12          AVM[a](#acm20197-tbl-note-0002){ref-type="fn"}   35      Male       1.612          1.861                        2.092                      12.401
  13          AVM                                              35      Female     3.803          2.174                        2.393                      10.066
  14          AVM                                              58      Female     4.532          1.988                        2.254                      13.390
  15          AVM                                              26      Female     6.289          1.920                        2.080                      8.351
  16          Glomus Tumor                                     66      Female     3.537          1.679                        1.749                      4.136
  17          Glomus Tumor                                     39      Female     2.723          1.411                        1.447                      2.495
  18          Glomus Tumor                                     55      Female     4.525          1.484                        1.555                      4.764
  19          Pilocytic Astrocytomas                           50      Female     2.811          1.412                        1.539                      9.013
  20          Pituitary Adenoma                                48      Female     2.040          1.400                        1.441                      2.934
  21          Pineocytoma                                      38      Male       9.847          1.243                        1.287                      3.542
  22          Meningioma                                       60      Female     0.715          1.652                        1.787                      8.136
  23          Meningioma                                       45      Male       5.170          1.498                        1.539                      2.689
  24          Meningioma                                       63      Female     8.942          1.147                        1.160                      1.102
  25          Metastatic Lesion                                50      Male       0.168          1.354                        1.447                      6.823
  26          Metastatic Lesion                                76      Female     0.357          1.523                        1.605                      5.379
  27          Metastatic lesion                                71      Male       0.449          1.495                        1.589                      6.274
  28          Metastatic Lesion                                54      Male       0.782          1.306                        1.433                      9.715
  29          Metastatic Lesion                                53      Female     0.825          1.310                        1.407                      7.397
  30          Metastatic Lesion                                59      Female     0.864          1.519                        1.688                      11.129
  31          Metastatic Lesion                                63      Female     1.530          1.241                        1.272                      2.528
  32          Metastatic Lesion                                34      Female     2.583          1.421                        1.536                      8.069
  33          Metastatic Lesion                                80      Female     3.370          1.252                        1.296                      3.508
  34          Metastatic Lesion                                63      Female     4.019          1.239                        1.269                      2.455
  35          Metastatic Lesion                                81      Female     4.931          1.656                        1.738                      4.983
  36          Metastatic Lesion                                62      Female     7.602          1.541                        1.584                      2.817
  37          Metastatic Lesion                                37      Male       10.187         1.153                        1.174                      1.838
  38          Metastatic Lesion                                55      Female     14.024         1.382                        1.497                      8.319
  39          Metastatic Lesion                                68      Male       19.112         1.194                        1.268                      6.204
  40          Metastatic Lesion                                48      Male       19.240         1.471                        1.513                      2.843
  41          Metastatic Lesion                                48      Male       24.136         1.430                        1.487                      3.963
  42          Metastatic Lesion                                48      Male       31.128         1.403                        1.468                      4.624
  43          Metastatic Lesion                                48      Male       45.576         1.317                        1.380                      4.798

Arteriovenous malformation

![The percentage difference of the conformity indices between $\text{MLC}_{5}$ and $\text{MLC}_{2.5}$ versus target volume.](ACM2-11-197-g005){#acm20197-fig-0005}

[Figure 6](#acm20197-fig-0006){ref-type="fig"} shows dose volume histograms of the 1 cm normal tissue shell surrounding representative target volumes. In this figure, the normal tissue volume receiving doses between 20--80% of the prescription dose is reduced when $\text{MLC}_{2.5}$ is used. Comparison of the normal tissue sparing capabilities of the $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ is shown in [Fig. 7](#acm20197-fig-0007){ref-type="fig"} and [Table 3](#acm20197-tbl-0003){ref-type="table-wrap"}. As illustrated by this data, $\text{NTV}_{50}$, $\text{NTV}_{70}$ and $\text{NTV}_{90}$ for $\text{MLC}_{2.5}$ plans were reduced significantly, resulting in positive NTD values in each case.

###### 

Conformity distance index (CDI) and normal tissue difference (NTD) between $\text{MLC}_{2.5}$ and $\text{MLC}_{5}$ in cm^3^ of volume receiving 50%, 70% and 90% of the prescription isodose.

  *Case \#*   $TV(cm^{3})$   $NTD_{50}(cm^{3})$   $NTD_{70}(cm^{3})$   $NTD_{90}(cm^{3})$   $\mathit{CDI‐MLC}_{2.5}(mm)$   $CDI‐MLC_{5}(mm)$
  ----------- -------------- -------------------- -------------------- -------------------- ------------------------------ -------------------
  1           0.070          0.210                0.071                0.007                1.41                           1.87
  2           0.187          1.167                0.547                0.148                1.39                           1.65
  3           0.327          1.632                0.889                0.349                1.88                           2.35
  4           0.351          1.765                0.950                0.350                1.83                           2.38
  5           0.382          1.743                1.103                0.560                1.55                           1.75
  6           0.411          1.992                1.232                0.488                1.96                           2.25
  7           0.505          2.034                1.293                0.560                1.84                           2.35
  8           0.823          1.543                1.009                0.484                1.83                           2.13
  9           0.836          1.504                0.988                0.356                1.18                           2.05
  10          0.867          1.344                0.752                0.224                1.16                           1.85
  11          1.103          1.660                0.951                0.429                1.85                           2.29
  12          1.612          2.052                1.412                0.732                3.33                           3.87
  13          3.803          4.004                1.568                0.432                3.53                           4.14
  14          4.532          4.182                3.374                1.919                3.61                           4.04
  15          6.289          4.388                3.192                2.224                4.30                           6.15
  16          3.537          0.168                1.005                0.560                2.06                           2.29
  17          2.723          2.624                1.640                0.584                1.57                           1.59
  18          4.525          0.504                1.204                0.812                2.29                           2.96
  19          2.811          3.273                1.965                1.110                2.10                           2.85
  20          2.040          1.764                0.932                0.246                1.63                           1.97
  21          9.847          5.064                2.768                1.744                2.08                           2.88
  22          0.715          1.448                0.679                0.233                1.66                           1.78
  23          5.170          2.848                1.132                0.836                1.96                           2.28
  24          8.942          4.136                2.528                0.912                1.79                           2.29
  25          0.168          0.448                0.203                0.055                1.98                           2.31
  26          0.357          1.254                0.752                0.213                0.96                           1.37
  27          0.449          0.916                0.504                0.210                0.92                           1.45
  28          0.782          1.388                0.782                0.301                1.86                           2.14
  29          0.825          1.024                0.660                0.288                1.26                           1.65
  30          0.864          0.616                0.376                0.176                1.91                           1.99
  31          1.530          0.836                0.432                0.120                1.92                           2.26
  32          2.583          2.788                2.252                0.696                1.65                           2.49
  33          3.370          2.400                1.276                0.416                1.37                           2.84
  34          4.019          2.832                1.680                0.608                1.32                           1.46
  35          4.931          3.523                2.598                1.211                2.56                           2.81
  36          7.602          2.584                1.672                0.456                2.92                           3.52
  37          10.187         4.530                2.556                1.390                1.62                           1.77
  38          14.024         3.680                3.032                0.996                3.47                           4.37
  39          19.112         3.548                2.284                1.888                3.21                           3.69
  40          19.240         5.024                4.520                2.296                3.23                           3.79
  41          24.136         7.056                6.160                1.240                3.72                           4.54
  42          31.128         6.488                7.288                4.248                4.53                           5.24
  43          45.576         7.161                8.360                5.832                4.84                           5.47

![Dose volume histograms of the normal tissue shell surrounding target for three patients.](ACM2-11-197-g006){#acm20197-fig-0006}

![Normal tissue difference NTD plotted as a function of target volume for tissue irradiated to 50%, 70% and 90% when $\text{MLC}_{2.5}$ is used instead of $\text{MLC}_{5}$.](ACM2-11-197-g007){#acm20197-fig-0007}

[Table 3](#acm20197-tbl-0003){ref-type="table-wrap"} also shows the values of CDI for all cases using both MLCs. The values of this parameter ranged were 0.9 to 4.8 mm for $\text{MLC}_{2.5}$ and from 1.37 to 6.15 mm for $\text{MLC}_{5}$. The values of CDI indicate that the $\text{MLC}_{2.5}$ is more suitable than $\text{MLC}_{5}$ for highly complex shaped targets.

IV. DISCUSSION {#acm20197-sec-0014}
==============

Our study shows that the dose conformity of the $\text{MLC}_{2.5}$ is significantly better than $\text{MLC}_{5}$. For target volumes ranging from 0.07 to $45.6\,\text{cm}^{3}$, the $\text{MLC}_{2.5}$ CI improved by an average of 7.3%. For small targets such as acoustic nueroma ($< 1.1\,\text{cm}^{3}$), an average CI improvement was 11% for $\text{MLC}_{2.5}$ plans. For our cohort of patients studied (see [Table 2](#acm20197-tbl-0002){ref-type="table-wrap"}), the CI was always better when $\text{MLC}_{2.5}$ was used, with the greatest CI difference of 18% seen for a lesion of $0.35\,\text{cm}^{3}$.

Our study showed that the overall average difference in the CI between the two MLCs increases from 4.6% for the simulated spherical cases to 7.3% for the patients in this study. Since the shape of a spherical target is simple and targets of actual patients are more complex, these results suggest that $\text{MLC}_{2.5}$ yields better conformity for complex tumor shape than $\text{MLC}_{5}$.

Our results showed that the CDI values for all tumor sizes and shapes studied were less when $\text{MLC}_{2.5}$ was used compared to those with $\text{MLC}_{5}$. The CDI values were higher for highly complex targets (such as in case 16 which is an AVM) and low for uniform shapes (such as in case 27) as shown in [Table 3](#acm20197-tbl-0003){ref-type="table-wrap"}.

The $\text{MLC}_{2.5}$ is a better choice to treat SRS target volume with DCA treatment technique particularly for small lesions and geometrically complex tumors. Other investigators have reported modest but statistically significant improvements using small leaf MLCs.^(^ [^9^](#acm20197-bib-0009){ref-type="ref"} ^,^ [^11^](#acm20197-bib-0011){ref-type="ref"} ^,^ [^13^](#acm20197-bib-0013){ref-type="ref"} ^,^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ In particular, investigators from other institutions compared 3 mm leaf width MLC ($\text{MLC}_{3\text{mm}}$) with $\text{MLC}_{5}$ and reported better target conformity and tissue sparing with the $\text{MLC}_{3\text{mm}}$.^(^ [^14^](#acm20197-bib-0014){ref-type="ref"} ^,^ [^17^](#acm20197-bib-0017){ref-type="ref"} ^,^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ Hazard et al.^(^ [^11^](#acm20197-bib-0011){ref-type="ref"} ^)^ compared linear accelerator‐based SRS using DCA with a Gamma Knife system and reported that accelerator‐based SRS provided comparable treatment conformity. Thus, $\text{MLC}_{2.5}$ linear accelerator‐based SRS system should offer at least equivalent conformity when compared with Gamma Knife systems. With both simulated targets and actual patient tumors, the difference in the conformity indices between $\text{MLC}_{5}$ and $\text{MLC}_{2.5}$ decreased with target volume ([Fig. 3](#acm20197-fig-0003){ref-type="fig"} and 5). Two separate studies reported in the literature^(^ [^17^](#acm20197-bib-0017){ref-type="ref"} ^,^ [^18^](#acm20197-bib-0018){ref-type="ref"} ^)^ found similar trends, whereas Monk et al.^(^ [^14^](#acm20197-bib-0014){ref-type="ref"} ^)^ did not report any dependence of CI on target volume.

[Figures 4](#acm20197-fig-0004){ref-type="fig"}, [6](#acm20197-fig-0006){ref-type="fig"} and [7](#acm20197-fig-0007){ref-type="fig"} show that using $\text{MLC}_{2.5}$ improves normal tissue sparing. [Figure 7](#acm20197-fig-0007){ref-type="fig"} shows that NTD increased with target volume and its values were always positive, suggesting better normal tissue sparing with the use of $\text{MLC}_{2.5}$ compared to $\text{MLC}_{5}$. Based on our analysis, $\text{MLC}_{2.5}$ provides better normal tissue sparing than $\text{MLC}_{5}$ for intracranial lesions even where the CI difference is modest. This is significant for a patient where the tumor is located close to the brainstem or the optic chiasm. In this scenario, the $\text{MLC}_{2.5}$ could offer a conformal therapeutic dose to the target volume while providing a lower dose for the adjacent critical structure. For such a patient, the dose to critical structure could prohibit the treatment using the $\text{MLC}_{5}$.

V. CONCLUSIONS {#acm20197-sec-0015}
==============

The $\text{MLC}_{2.5}$ has a dosimetric advantage over the $\text{MLC}_{5}$ both in the treatment conformity (CI and CDI) and normal tissue sparing when target shape complexity increases. The $\text{MLC}_{2.5}$ has an advantage particularly when the critical structures are adjacent to the target volume. The use of $\text{MLC}_{2.5}$ improved the plan conformity for small lesions ($< 1.1\,\text{cm}^{3}$) on average by 11%, as compared to the $\text{MLC}_{5}$. In summary, the $\text{MLC}_{2.5}$ has the potential to provide improved dose conformity to the target volume and lower doses to critical structures compared with standard MLCs such as $\text{MLC}_{5}$. The 2.5 mm leaf width for an MLC represents a new standard for linear accelerator‐based radiosurgery.
